These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34675989)

  • 1. Levels of Serum sST2, MMP-3, and Gal-3 in Patients with Essential Hypertension and Their Correlation with Left Ventricular Hypertrophy.
    Wang X; Han W; Han L; Yang J; Li K; Fan Y
    Evid Based Complement Alternat Med; 2021; 2021():7262776. PubMed ID: 34675989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of soluble ST2 in patients with essential hypertension and its relationship with left ventricular hypertrophy.
    Wei P; Liu L; Wang X; Zong B; Liu X; Zhang M; Fu Q; Wang L; Cao B
    ESC Heart Fail; 2023 Feb; 10(1):303-310. PubMed ID: 36210061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy.
    Gawor M; Śpiewak M; Janas J; Kożuch K; Wróbel A; Mazurkiewicz Ł; Baranowski R; Marczak M; Grzybowski J
    Kardiol Pol; 2017; 75(10):997-1004. PubMed ID: 28612913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating MicroRNA-30e Predicts Left Ventricular Hypertrophy In Essential Hypertensive Patients.
    Xu H; Xu Y; Yang J; Juang J
    Rev Invest Clin; 2020 Dec; ():. PubMed ID: 33262538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of benidipine hydrochloride on severe left ventricular hypertrophy and collagen metabolism in patients with essential hypertension.
    Hirono O; Fatema K; Nitobe J; Takeishi Y; Kaneko K; Shiga R; Kubota I
    J Cardiol; 2002 Apr; 39(4):195-204. PubMed ID: 11977767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of galectin-3 to left ventricular geometry and hypertrophy in chronic hemodialysis patients.
    Yilmaz H; Gurel OM; Celik HT; Bozkurt A; Yildirim ME; Bilgic I; Bilgic MA; Bavbek N; Akcay A
    Herz; 2015 Jun; 40(4):702-8. PubMed ID: 24924396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ventricular remodeling and matrix metalloproteinase-1 and its tissue inhibitor of metalloproteinase-1 in serum in third trimester of pregnant women with cardiac disease.].
    Zhang ZL; Lin JH; Tao RQ
    Zhonghua Fu Chan Ke Za Zhi; 2009 Oct; 44(10):731-5. PubMed ID: 20078957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble ST2, Galectin-3 and clinical prognosis of patients with hypertrophic cardiomyopathy undergoing ventricular septal myectomy: a correlation analysis.
    Song B; Yao B; Dang H; Dong R
    Cardiovasc Diagn Ther; 2020 Apr; 10(2):145-152. PubMed ID: 32420094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deficiency of Tregs in hypertension-associated left ventricular hypertrophy.
    Tang Y; Shen L; Bao JH; Xu DY
    J Clin Hypertens (Greenwich); 2023 Jun; 25(6):562-572. PubMed ID: 37196041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of alterations of serum inflammatory cytokines and fibrosis makers in patients with essential hypertension and left ventricular hypertrophy and the risk factors.
    Li X; Guo X; Chang Y; Zhang N; Sun Y
    Am J Transl Res; 2022; 14(6):4097-4103. PubMed ID: 35836904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between Soluble ST2 and Left Ventricular Geometry in Maintenance Hemodialysis Patients.
    Zhang Z; Xie Y; Shen B; Nie Y; Cao X; Xiang F; Zou J
    Blood Purif; 2021; 50(1):84-92. PubMed ID: 33291107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential prognostic value of ultrasonic characterization (videodensitometry) of myocardial tissue in essential arterial hypertension.
    Di Bello V; Pedrinelli R; Giorgi D; Bertini A; Talini E; Caputo MT; Dell'Omo G; Cioppi A; Moretti L; Paterni M; Giusti C
    Coron Artery Dis; 2000 Oct; 11(7):513-21. PubMed ID: 11023238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum osteopontin, but not OPN gene polymorphism, is associated with LVH in essential hypertensive patients.
    Hou X; Hu Z; Huang X; Chen Y; He X; Xu H; Wang N
    J Mol Med (Berl); 2014 May; 92(5):487-95. PubMed ID: 24370940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Myocardial hypertrophy and coronary insufficiency as a cause of arrhythmia in patients with hypertension].
    Israpilov MM; Gerashchenko IuS; Fofanova TV; Iurenev AP
    Ter Arkh; 1999; 71(4):37-40. PubMed ID: 10358861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of losartan on left ventricular hypertrophy and plasma transforming growth factor-beta1 in elderly patients with hypertension].
    Wu ZL; Xu DL; Li Y; Lai WY; Huang P; Bai SC; Su L
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Mar; 29(3):531-3. PubMed ID: 19304546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Four-Dimensional Volume-Strain Expression in Asymptomatic Primary Hypertension Patients Presenting with Subclinical Left Atrium-Ventricle Dysfunction.
    Ran H; Schneider M; Wan LL; Ren JY; Ma XW; Zhang PY
    Cardiology; 2020; 145(9):578-588. PubMed ID: 32756051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertensive left ventricular hypertrophy: relation to beta-adrenergic receptor kinase-1 (betaARK1) in peripheral lymphocytes.
    Park SJ; Choi DJ; Kim CW
    J Hypertens; 2004 May; 22(5):1025-32. PubMed ID: 15097244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Study on changes of plasma substance P in essential hypertension with left ventricular hypertrophy patients and the effect of promoting blood circulation and eliminating phlegm].
    Yan C; Gao M; Deng Z
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 1998 Jun; 18(6):336-8. PubMed ID: 11477905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The prognostic value of circulating microRNA-29b in left ventricular hypertrophy in patients with hypertension].
    Zhou XH; Cai JP; Liu WL; Zhang X; Wu XJ; Gao CY
    Zhonghua Nei Ke Za Zhi; 2019 Apr; 58(4):278-281. PubMed ID: 30917420
    [No Abstract]   [Full Text] [Related]  

  • 20. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.